Intervacc is trading at €0.05, down 3.61%, with the reason for the decline unclear. - On November 3, Intervacc said only three confirmed infections occurred among horses completing primary vaccination after 100,000 Strangvac doses had been sold; this positive news does not explain the November 4 decline. - Supplied sector context showed biotech higher, not lower, so it does not account for the drop. - Available coverage identified no clear same-day company-specific catalyst or supporting reason; the cause remains unclear.